OUR TESTS AIM TO DETECT CANCER EARLIER – WHEN TREATMENT CAN BE MOST EFFECTIVE FOR PATIENTS
fighting cancer by Early detection
OUR TESTS AIM TO DETECT CANCER EARLIER – WHEN TREATMENT CAN BE MOST EFFECTIVE FOR PATIENTS
fighting cancer by Early detection
OUR TESTS AIM TO DETECT CANCER EARLIER – WHEN TREATMENT CAN BE MOST EFFECTIVE FOR PATIENTS
fighting cancer by Early detection
Bladder EpiCheck®, CE-marked and available in Europe for primary and recurrent bladder cancer and upper tract urinary cancer, and FDA 510(k) cleared for bladder cancer recurrence in the United States.
In development
Detect early stage lung cancer in high-risk individuals with a simple blood test
Lung PageNucleix R&D has the capabilities and experience to develop additional liquid biopsy assays for other types of cancer
DELIVERING HIGHLY ACCURATE AND SENSITIVE RESULTS WITH A SEAMLESS TESTING OPTION FOR PATIENTS AND THE HEALTHCARE SYSTEM
Technology PageWe are working with leading medical centers, organizations and laboratories worldwide
Go to the inbox of the email
address you just used to sign up.
Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “info@nucleix.com”.
Click on the link inside the <br>email and you’re good to go.
